Your browser doesn't support javascript.
loading
Safety, feasibility of intravenous and intrathecal injection of autologous bone marrow derived mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: An open label phase I clinical trial
Cell Journal [Yakhteh]. 2019; 20 (4): 592-598
in English | IMEMR | ID: emr-199631
Responsible library: EMRO
ABSTRACT

Objective:

Amyotrophic lateral sclerosis [ALS] is the most severe disorder within the spectrum of motor neuron diseases [MND] that has no effective treatment and a progressively fatal outcome. We have conducted two clinical trials to assess the safety and feasibility of intravenous [IV] and intrathecal [IT] injections of bone marrow derived mesenchymal stromal cells [BM-MSCs] in patients with ALS
Search on Google
Index: IMEMR (Eastern Mediterranean) Language: English Journal: Cell J. [Yakhteh] Year: 2019

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Index: IMEMR (Eastern Mediterranean) Language: English Journal: Cell J. [Yakhteh] Year: 2019